Resverlogix Company Description

Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses.

The company’s lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein cholesterol, recent acute coronary syndrome, and post COVID-19 conditions.

It has a partnership with Eversana Life Science Services, LLC to support the commercialization of apabetalone for COVID-19 in the United States and Canada; and developing cardiovascular and pulmonary arterial hypertension indications.

The company is headquartered in Calgary, Canada.

Resverlogix Corp.

Country	Canada
Industry	Biotechnology
Sector	Healthcare
Employees	19
CEO	Donald McCaffrey

Contact Details

Address: 4820 Richard Road SW Calgary, Alberta T3E 6L1 Canada
Phone	403 254 9252
Website	resverlogix.com

Stock Details

Ticker Symbol	RVX
Exchange	Toronto Stock Exchange
Fiscal Year	January - December
Reporting Currency	USD
ISIN Number	CA76128M1086
SIC Code	2836

Key Executives

Name	Position
Donald J. McCaffrey	Co-Founder, Chairman, President, Chief Executive Officer and Secretary
Aaron Bradley Cann C.A., CPA, CBV	Chief Financial Officer
Dr. Ewelina Kulikowski Ph.D.	Chief Scientific Officer
Dr. Michael Sweeney M.D.	Senior Vice President of Clinical Development